Reality of the ASPIRE Study

Ajai Chari, MD

Video Categories: ASH 2014

Ajai Chari, MD, at the Mount Sinai School of Medicine in New York, deliberates on the results of the ASPIRE study as the most important thing to come out of ASH for the myeloma community. He mentions that although the study has very positive indications, the therapy isn’t really appropriate for a large portion of the myeloma population. The most practice changing piece of the study may be regarding the proven safety of carfilzomib.

Related Videos

August 29, 2018

How PD-L1 Biomarker Test Results Impact Clinical Management of Lung Cancer

Drs. Goeffrey Oxnard and Lauren Ritterhouse review how the results of PD-L1 testing influence the choices in first- or second-line immunotherapy or combination immunochemotherapy in patients with squamous or non-squamous non-small-cell lung cancer.

December 3, 2013

The Impact of Hedgehog Pathway Inhibitors on the Management of Patients with Basal Cell Carcinoma

In this third WCMC clinical commentary entitled, Basal Cell Carcinoma Case Studies in Hedgehog Pathway Inhibition Radiation, Joel Claveau, MD, CSPQ, FRCPC; Dirk Schadendorf, MD; Nicole Basset-Seguin, MD, PhD and Aleksandar Sekulic, MD, PhD discuss different case studies where patients were successfully treated by Hedgehog Pathway Inhibitors.